A new
survey conducted by researchers at Boston's Mass General Brigham (MGB) healthcare system found that perimenopausal and postmenopausal women had similar patterns of use for cannabis to treat their menopausal symptoms.
The paper, published in published in Menopause, the journal of the The North American Menopause Society (NAMS), had this to say (with full citations) about the potential for cannabinoid treatments for menopause symptoms:
The endocannabinoid system is involved in a variety of physiological and
psychological processes (e.g., regulating body temperature, mood,
anxiety, sleep), and evidence suggests that this system significantly
impacts fertility and reproduction. Specifically, the human ovary produces the endogenous cannabinoid
anandamide with peak plasma levels occurring at ovulation and
correlating with estrogen levels, suggesting that anandamide production
may be controlled by this hormone.
In addition,
cannabinoid treatments, including administration of
anandamide, as well as antagonists of cannabinoid degradative enzymes,
improve postovariectomy complications and reduce anxiety.
Further, administration of cannabinoids typically results in
vasorelaxation [reduction in tension of the blood vessel walls],
suggesting that cannabinoid-based therapies may be particularly
salient for treating vasomotor symptoms of menopause [hot flashes and
night sweats].
In particular, estrogen deficiency results in downregulation of systems
involved in hemodynamic regulation and is associated with vasomotor
symptoms; 2 weeks of treatment with anandamide has been shown to reverse
this downregulation in ovariectomized rats.
Taken together, research indicates that medical cannabis (MC) may be a
nonhormone treatment option with the potential to alleviate
menopause-related symptoms with greater efficacy and possibly fewer side
effects relative to existing treatments.